Tango Therapeutics (TNGX) Revenue & Revenue Breakdown
Tango Therapeutics Revenue Highlights
Latest Revenue (Y)
$36.53M
Latest Revenue (Q)
$6.47M
Main Segment (Y)
Collaboration Revenue
Main Geography (Y)
Collaboration Revenue
Tango Therapeutics Revenue by Period
Tango Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $36.53M | 46.93% |
| 2022-12-31 | $24.86M | -32.89% |
| 2021-12-31 | $37.04M | 383.83% |
| 2020-12-31 | $7.66M | -68.94% |
| 2019-12-31 | $24.65M | - |
Tango Therapeutics generated $36.53M in revenue during NA 2023, up 46.93% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Tango Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $6.47M | 19.15% |
| 2023-12-31 | $5.43M | -49.39% |
| 2023-09-30 | $10.73M | -26.48% |
| 2023-06-30 | $14.60M | 153.17% |
| 2023-03-31 | $5.77M | -10.06% |
| 2022-12-31 | $6.41M | -7.36% |
| 2022-09-30 | $6.92M | 19.91% |
| 2022-06-30 | $5.77M | 0.23% |
| 2022-03-31 | $5.76M | 0.73% |
| 2021-12-31 | $5.72M | -15.78% |
| 2021-09-30 | $6.79M | -62.61% |
| 2021-06-30 | $18.15M | 184.26% |
| 2021-03-31 | $6.39M | -30.15% |
| 2020-12-31 | $9.14M | -181.18% |
| 2020-09-30 | $-11.26M | -322.37% |
| 2020-06-30 | $5.06M | 7.49% |
| 2020-03-31 | $4.71M | - |
Tango Therapeutics generated $6.47M in revenue during Q1 2024, up 19.15% compared to the previous quarter, and up 100.94% compared to the same period a year ago.
Tango Therapeutics Revenue Breakdown
Tango Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| License Revenue | $5.00M | $11.00M | - |
| Collaboration Revenue | $31.53M | $24.86M | $26.04M |
Tango Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration Revenue (86.31%), and License Revenue (13.69%).
Quarterly Revenue by Product
| Product/Service | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue | $11.20M | $10.73M | $9.60M | $6.41M | $6.92M | $5.77M | $5.72M | $6.79M |
| License Revenue | - | $5.00M | $5.00M | - | $11.00M | - | - | - |
Tango Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Collaboration Revenue (100.00%).
Tango Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 22 | Dec 21 |
|---|---|---|
| Collaboration Revenue | $24.86M | $26.04M |
| License Revenue | - | $11.00M |
Tango Therapeutics's latest annual revenue breakdown by geography, as of Dec 22: Collaboration Revenue (100.00%).
Tango Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KYMR | Kymera Therapeutics | $78.59M | $3.74M |
| ARVN | Arvinas | $78.50M | $102.40M |
| NRIX | Nurix Therapeutics | $76.99M | $12.59M |
| TNGX | Tango Therapeutics | $36.53M | $6.47M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| RLAY | Relay Therapeutics | $25.55M | - |
| RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.22M |
| STTK | Shattuck Labs | $1.66M | $1.61M |
| PLRX | Pliant Therapeutics | $1.58M | - |
| BCEL | Atreca | $770.00K | $80.00K |
| CGEM | Cullinan Oncology | - | - |
| RAPT | RAPT Therapeutics | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| RLYB | Rallybio | - | $299.00K |
| CNTB | Connect Biopharma | - | - |
| PASG | Passage Bio | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| THRD | Third Harmonic Bio | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| TYRA | Tyra Biosciences | - | - |
| XLO | Xilio Therapeutics | - | $2.36M |
TNGX Revenue FAQ
What is Tango Therapeutics’s yearly revenue?
Tango Therapeutics's yearly revenue for 2023 was $36.53M, representing an increase of 46.93% compared to 2022. The company's yearly revenue for 2022 was $24.86M, representing a decrease of -32.89% compared to 2021. TNGX's yearly revenue for 2021 was $37.04M, representing an increase of 383.83% compared to 2020.
What is Tango Therapeutics’s quarterly revenue?
Tango Therapeutics's quarterly revenue for Q1 2024 was $6.47M, a 19.15% increase from the previous quarter (Q4 2023), and a 12.23% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $5.43M, a -49.39% decrease from the previous quarter (Q3 2023), and a -15.29% decrease year-over-year (Q4 2022). TNGX's quarterly revenue for Q3 2023 was $10.73M, a -26.48% decrease from the previous quarter (Q2 2023), and a 55.09% increase year-over-year (Q3 2022).
What is Tango Therapeutics’s revenue growth rate?
Tango Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -1.39%, and for the last 5 years (2019-2023) was 48.19%.
What are Tango Therapeutics’s revenue streams?
Tango Therapeutics's revenue streams in c 23 are License Revenue, and Collaboration Revenue. License Revenue generated $5M in revenue, accounting 13.69% of the company's total revenue, down -54.55% year-over-year. Collaboration Revenue generated $31.53M in revenue, accounting 86.31% of the company's total revenue, up 26.82% year-over-year.
What is Tango Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Tango Therapeutics was Collaboration Revenue. This segment made a revenue of $31.53M, representing 86.31% of the company's total revenue.